CF33-CD19

AXP000101.1 · Oncolytic virus

Platform
chimeric orthopoxvirus (CF33)
Originator
City of Hope (Yuman Fong)
Sponsor
Imugene

Names

NameTypeSource
CF33-CD19preferred name, codecurator, ncit
onCARlyticsbrandncit
CF33-CD19tcodecurator

Virus

Role
Oncolytic
Family
Poxviridae
Virus
chimeric orthopoxvirus (CF33)
Strain
CF33
Replication
conditionally replicating
Modifications
engineered to express truncated human CD19 on infected tumour cells
Transgenes
CD19 (truncated)
Route
intratumoral, intravenous
Source
evidence

Cross-references

NCI Thesaurus
C201773

Approvals

No regulatory approval recorded.

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT06063317A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)TerminatedPhase 12023-10-022026-02-0225Solid Tumor, Adult

Recent changes

No changes recorded in its trials yet.

Clinical papers

No confirmed clinical papers yet.

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 38214445Using Oncolytic Virus to Retask CD19-Chimeric Antigen Receptor T Cells for Treatment of Pancreatic Cancer: Toward a Universal Chimeric Antigen Receptor T-Cell Strategy for Solid Tumor.Journal of the American College of Surgeons2024name in abstract: CF33-CD19t

Notes

Trade-named onCARlytics: paints tumour cells with truncated CD19 so that anti-CD19 agents (blinatumomab, CAR-T) can act. First patient dosed in the phase 1 OASIS trial in October 2023.

How to cite

CF33-CD19 (AXP000101.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000101.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.